AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1923103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosine arabinoside (Ara-C) 100 mg/m2 12 hourly for seven days and daunorubicin (DNR) 45 mg/m2 daily for three days followed by three further courses of Ara-C (five days) and DNR (two days) in the same dosage.
Number of subjects: 92
Study 1923103 — intervention group
Group type: COMPARATOR
Intervention: Three courses of VP16 100 mg/m2 daily for five days and one dose of mAMSA of 200 mg/m2 as postremission consolidation.
Number of subjects: 92
Study 1923103 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment protocol.
Number of subjects: 92
Study 7462667 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA + UVB irradiation
Number of subjects: 8
Study 7462667 — intervention group
Group type: COMPARATOR
Intervention: UVB irradiation
Number of subjects: 8
Study 31566129 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 32
Study 30585454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (ginger-separated snake moxibustion), 3 cones per session, once a week for 12 weeks
Number of subjects: 90
Study 30585454 — intervention group
Group type: COMPARATOR
Intervention: Control A group (no specific intervention mentioned)
Number of subjects: 90
Study 30585454 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion treatment
Number of subjects: 90
Study 30585454 — intervention group
Group type: COMPARATOR
Intervention: Control A group
Number of subjects: 90
Study 30585454 — intervention group
Group type: COMPARATOR
Intervention: Control B group (normal subjects)
Number of subjects: 90
Study 27179849 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coils treatment (n=158)
Number of subjects: 315
Study 27179849 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=157)
Number of subjects: 315
Study 24383406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment of Insomnia (BBTI)
Number of subjects: 30
Study 24383406 — intervention group
Group type: COMPARATOR
Intervention: Information Control (IC)
Number of subjects: 30
Study 22103435 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% nadifloxacin combined with topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin)
Number of subjects: 40
Study 22103435 — intervention group
Group type: COMPARATOR
Intervention: Topical anti-acne products (adapalene, benzoyl peroxide, azelaic acid, isotretinoin) alone
Number of subjects: 40
Study 22103435 — intervention group
Group type: COMPARATOR
Intervention: Untreated control area
Number of subjects: 40
Study 19021624 — intervention group
Group type: EXPERIMENTAL
Intervention: PNB combined with Antrolin cream (group B)
Number of subjects: 200
Study 19021624 — intervention group
Group type: COMPARATOR
Intervention: PNB alone (group A)
Number of subjects: 200
Study 18210825 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone protocol plus extended transsternal thymectomy (ETTX)
Number of subjects: 0
Study 18210825 — intervention group
Group type: COMPARATOR
Intervention: Prednisone protocol alone
Number of subjects: 0
Study 15870631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior heavy exercise (three 73-s efforts at 90% CP)
Number of subjects: 11
Study 15870631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior severe exercise (three 60-s efforts at 110% CP)
Number of subjects: 11
Study 15870631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior heavy exercise
Number of subjects: 11
Study 15870631 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior severe exercise
Number of subjects: 11
Study 15870631 — intervention group
Group type: COMPARATOR
Intervention: Control trial (CON)
Number of subjects: 11
Study 11833753 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-enhancing oral formula (Advera)
Number of subjects: 90
Study 11833753 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard oral formula (Ensure Plus)
Number of subjects: 90
Study 11833753 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 9933772 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidek EAS‐1000 retroillumination image analysis
Number of subjects: 450
Study 9933772 — intervention group
Group type: COMPARATOR
Intervention: Standard pupil size analyses
Number of subjects: 450
Study 9933772 — intervention group
Group type: COMPARATOR
Intervention: Maximal pupil size analyses
Number of subjects: 450
Study 8583780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 25 mg
Number of subjects: 25
Study 8583780 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low doses of HCTZ and furosemide (FU)
Number of subjects: 25
Study 8583780 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (FU)
Number of subjects: 25
Study 8583780 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 25
Study 8583780 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with advanced renal failure)
Number of subjects: 25
Study 2182314 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 44000
Study 2182314 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality adjuvant therapy
Number of subjects: 44000
Study 342639 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer immune serum globulin (3-ml injections, two doses, four months apart)
Number of subjects: 566
Study 342639 — intervention group
Group type: COMPARATOR
Intervention: Low-titer immune serum globulin (3-ml injections, two doses, four months apart)
Number of subjects: 566
Study 29915021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lixisenatide 20 μg
Number of subjects: 34
Study 29915021 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine
Number of subjects: 34
Study 26291425 — intervention group
Group type: EXPERIMENTAL
Intervention: Valethamate bromide
Number of subjects: 158
Study 26291425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 23774314 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose corticosteroids (HDS; hydrocortisone, 100 mg, intravenously 3 times daily, followed by taper)
Number of subjects: 92
Study 23774314 — intervention group
Group type: COMPARATOR
Intervention: Low-dose corticosteroids (LDS; intravenous hydrocortisone equivalent to presurgical oral dosing, followed by taper)
Number of subjects: 92
Study 22583760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg followed by infusion during the procedure; n = 198)
Number of subjects: 401
Study 22583760 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 75 IU/kg; n = 203)
Number of subjects: 401
Study 22583760 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 401
Study 22583760 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 401
Study 20555368 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (As group)
Number of subjects: 16
Study 20555368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl group)
Number of subjects: 16
Study 18781872 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI/3TC/EFV
Number of subjects: 369
Study 18781872 — intervention group
Group type: COMPARATOR
Intervention: COM/EFV
Number of subjects: 369
Study 15715270 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate-high-monounsaturated-fat (Glucerna)
Number of subjects: 104
Study 15715270 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate diet (Precitene Diabet)
Number of subjects: 104
Study 12401122 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 30
Study 12401122 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin 4 mg
Number of subjects: 30
Study 12401122 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg
Number of subjects: 30
Study 12401122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 30
Study 12401122 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg
Number of subjects: 30
Study 12401122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10546082 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 275
Study 8678264 — intervention group
Group type: EXPERIMENTAL
Intervention: hyaluronidase 150 iu.ml‐1
Number of subjects: 60
Study 8678264 — intervention group
Group type: COMPARATOR
Intervention: no hyaluronidase (control group)
Number of subjects: 60
Study 8678264 — intervention group
Group type: EXPERIMENTAL
Intervention: hyaluronidase 50 iu.ml‐1
Number of subjects: 60
Study 1690974 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin 5% (group 1)
Number of subjects: 40
Study 1690974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hetastarch 6% (group 2)
Number of subjects: 40
Study 550143 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (200 mmols/day)
Number of subjects: 13
Study 550143 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (40 mmols/day)
Number of subjects: 13
Study 550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion during low sodium diet
Number of subjects: 13
Study 550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextrose and water infusion during low sodium diet
Number of subjects: 13
Study 550143 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin or ibuprofen administration during saline and dextrose and water infusions
Number of subjects: 13
Study 31395900 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX-4 or XELOX adjuvant chemotherapy for 6 months
Number of subjects: 512
Study 27696750 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening and Stretching for Rheumatoid Arthritis of the Hand (SARAH) exercise program
Number of subjects: 0
Study 27696750 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 26239323 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion vancomycin (target random levels, 20‐30 mg/L)
Number of subjects: 130
Study 24077095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 400 μg/10 μg
Number of subjects: 66
Study 24077095 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FP/S) 460 μg/42 μg
Number of subjects: 66
Study 24077095 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol (MF/F) 200 μg/10 μg
Number of subjects: 66
Study 24077095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 21295941 — intervention group
Group type: EXPERIMENTAL
Intervention: Insall-Burstein II
Number of subjects: 84
Study 21295941 — intervention group
Group type: COMPARATOR
Intervention: NexGen Legacy
Number of subjects: 84
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT (bulk technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT (incremental technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Filtek Supreme XT (bulk technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Filtek Supreme XT (incremental technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Ribbond (bulk technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + Ribbond (incremental technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + everStick NET (bulk technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Supreme XT Flow + everStick NET (incremental technique)
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribbond fiber in composite
Number of subjects: 80
Study 19363973 — intervention group
Group type: EXPERIMENTAL
Intervention: everStick NET fiber in composite
Number of subjects: 80
Study 16571758 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest condition with stimulation at 4x pain threshold (PT)
Number of subjects: 10
Study 16571758 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement condition with stimulation at 4x pain threshold (PT)
Number of subjects: 10
Study 12514457 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 93
Study 12514457 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 93
Study 11057355 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride 0.1%
Number of subjects: 80
Study 11057355 — intervention group
Group type: COMPARATOR
Intervention: Ketotifen fumarate 0.05%
Number of subjects: 80
Study 9065359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Gross Function Section
Number of subjects: 51
Study 9065359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Arm Section
Number of subjects: 51
Study 9065359 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivermead Motor Assessment - Leg and Trunk Section
Number of subjects: 51
Study 7998413 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml HBIg at birth followed by hepatitis B immunization (20 micrograms) at 3, 4, 5 and 11 months (schedule E)
Number of subjects: 195
Study 7998413 — intervention group
Group type: EXPERIMENTAL
Intervention: HBIg at 3 months (schedule F)
Number of subjects: 195
Study 7998413 — intervention group
Group type: COMPARATOR
Intervention: Plasma vaccine (10 micrograms) according to schedule F (historic controls)
Number of subjects: 195
Study 3376877 — intervention group
Group type: COMPARATOR
Intervention: Nitrogen dioxide (NO2) exposure at 0.0 ppm (control)
Number of subjects: 59
Study 3376877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure at 0.3 ppm
Number of subjects: 59
Study 3376877 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO2) exposure at 0.6 ppm
Number of subjects: 59
Study 3376877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambient air exposure (mean NO2 concentration 0.086 +/- 0.024 ppm)
Number of subjects: 59
Study 30188231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy (carboplatin/cisplatin + pemetrexed)
Number of subjects: 0
Study 30188231 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + chemotherapy
Number of subjects: 0
Study 25611941 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education teachers
Number of subjects: 1357
Study 25611941 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurses
Number of subjects: 1357
Study 25611941 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 1357
Study 23712757 — intervention group
Group type: EXPERIMENTAL
Intervention: Danoprevir 100 mg and Ritonavir 100 mg co-administered with Ciclosporin 100 mg
Number of subjects: 18
Study 23712757 — intervention group
Group type: COMPARATOR
Intervention: Danoprevir 100 mg and Ritonavir 100 mg
Number of subjects: 18
Study 23712757 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin 100 mg
Number of subjects: 18
Study 20810374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing mastectomy
Number of subjects: 2482
Study 20810374 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy
Number of subjects: 2482
Study 18837608 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-identified KOL teachers and mental health providers (n = 12 KOLs and n = 21 providers)
Number of subjects: 61
Study 18837608 — intervention group
Group type: COMPARATOR
Intervention: Mental health provider consultation only (n = 54 teachers)
Number of subjects: 61
Study 16820345 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium potassium supplementation (magnesium, 70.8 mg/d; potassium, 217.2 mg/d) for four weeks
Number of subjects: 133
Study 16820345 — intervention group
Group type: COMPARATOR
Intervention: Lacidipine (4 mg/d) as control
Number of subjects: 133
Study 14524395 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ivermectin
Number of subjects: 0
Study 11119328 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal spraying with deltamethrin 5% SC at 25 mg a. i./m2 (PT group)
Number of subjects: 1541
Study 11119328 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal spraying with slow-release malathion 8.3% SR at 2g a. i./m2 (PL group)
Number of subjects: 1541
Study 11119328 — intervention group
Group type: COMPARATOR
Intervention: Conventional spraying with deltamethrin indoors and in the peridomicile (PT group)
Number of subjects: 1541
Study 11119328 — intervention group
Group type: COMPARATOR
Intervention: Conventional spraying with deltamethrin indoors and slow-release malathion in the peridomicile (PL group)
Number of subjects: 1541
Study 8763182 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime (30 mg/kg) at induction of anaesthesia
Number of subjects: 150
Study 8763182 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic
Number of subjects: 150
Study 1707255 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal intubation with an Atkinson tube (AT)
Number of subjects: 27
Study 1707255 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal intubation followed by radiation therapy (AT/RT)
Number of subjects: 27
Study 1707255 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser therapy followed by irradiation (L/RT)
Number of subjects: 27
Study 1707255 — intervention group
Group type: COMPARATOR
Intervention: AT group
Number of subjects: 27
Study 1707255 — intervention group
Group type: COMPARATOR
Intervention: L/RT group
Number of subjects: 27
Study 6177981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral human gammaglobulin
Number of subjects: 75
Study 6177981 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31959601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intervention (comprehensive 6‐monthly general practitioner consultations, supported by medication reviews and nurse appointments)
Number of subjects: 797
Study 31959601 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D intervention
Number of subjects: 797
Study 31959601 — intervention group
Group type: COMPARATOR
Intervention: usual care
Number of subjects: 797
Study 30137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Curriculum regarding LGBT medical care concepts
Number of subjects: 24
Study 30137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey and interview regarding LGBT curriculum at USU
Number of subjects: 24
Study 30137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Published curriculum
Number of subjects: 24
Study 30137522 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of faculty interviews
Number of subjects: 24
Study 28948690 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based support groups
Number of subjects: 203
Study 28948690 — intervention group
Group type: COMPARATOR
Intervention: Control condition (information)
Number of subjects: 203
Study 26031828 — intervention group
Group type: EXPERIMENTAL
Intervention: Arg infusion (0.5 g/kg, 30 min)
Number of subjects: 71
Study 26031828 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat protein meals
Number of subjects: 71
Study 26031828 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily Arg ingestion (10 g)
Number of subjects: 71
Study 26031828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 23906999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (100-300 mg/day)
Number of subjects: 106
Study 23906999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 23906999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 106
Study 20860717 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 2417
Study 20860717 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 2417
Study 20860717 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER 4 mg
Number of subjects: 2417
Study 20860717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2417
Study 20860717 — intervention group
Group type: EXPERIMENTAL
Intervention: fesoterodine
Number of subjects: 2417
Study 20860717 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER
Number of subjects: 2417
Study 19555253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day
Number of subjects: 241
Study 19555253 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg/day
Number of subjects: 241
Study 19555253 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day + Simvastatin 40 mg/day
Number of subjects: 241
Study 17698761 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical placement of an implantable telescope prosthesis
Number of subjects: 0
Study 15390343 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose alcohol (1.6 +/- 0.4 ml)
Number of subjects: 34
Study 15390343 — intervention group
Group type: COMPARATOR
Intervention: High dose alcohol (3.4 +/- 0.9 ml)
Number of subjects: 34
Study 11228295 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% (two drops)
Number of subjects: 19
Study 11228295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10197074 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) 6 i.u. s.c. twice daily from 2 days before until 7 days after surgery
Number of subjects: 24
Study 10197074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10197074 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 24
Study 10197074 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and Placebo
Number of subjects: 24
Study 7815310 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.1 mg/kg
Number of subjects: 77
Study 7815310 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.3 mg/kg
Number of subjects: 77
Study 7815310 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-hirudin, 0.5 mg/kg
Number of subjects: 77
Study 7815310 — intervention group
Group type: EXPERIMENTAL
Intervention: rec-hirudin, 1 mg/kg
Number of subjects: 77